Rajesh Krishna - Certara, USA Inc | 人才画像

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 17 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Pediatric Rare Diseases Development in the Pharmaceutical Industry: An International Consortium for Innovation and Quality in Pharmaceutical Development, Clinical Pharmacology Leadership Group-Pediatrics Working Group, Rare Diseases Subteam Whitepaper Examining the Current Landscape and Recommendations for the Future

Rajesh Krishna,Bernard Sebastien,Solange Corriol-Rohou,S Y Amy Cheung,Jing Liu,Satyendra Suryawanshi

Clinical pharmacology and therapeutics (2024)

引用0浏览0WOS引用

Advancing Pediatric Drug Development in South Asia: Current Landscape and Vision for the Future

Rajesh Krishna,Manoj Jadhav,Rama Sivasubramanian,Gangadhar Sunkara, Vikram Gota,Vis Niranjan,Vipin Dhote,Nidhi Sapkal,Nirmala N Rege, Samir Sethi,Bikash Medhi,Nilima Kshirsagar, Deven Parmar

Indian journal of pharmacologyno. 4 (2024): 285-289

引用0浏览0WOS引用

Getting the Dose Right in Drug Development for Rare Diseases: Barriers and Enablers

Mariam A Ahmed,Rajesh Krishna, Noha Rayad,Salwa Albusaysi,Amitava Mitra, Elizabeth Shang,Yuen Yi Hon,Bilal AbuAsal,Rana Bakhaidar,Youssef M Roman,Indranil Bhattacharya,James Cloyd,Munjal Patel,Reena V Kartha,Islam R Younis

Clinical pharmacology and therapeutics (2024)

引用0浏览0WOS引用

New Horizons of Model Informed Drug Development in Rare Diseases Drug Development

Amitava Mitra, Nessy Tania,Mariam A Ahmed, Noha Rayad,Rajesh Krishna,Salwa Albusaysi,Rana Bakhaidar, Elizabeth Shang,Maria Burian,Michelle Martin-Pozo,Islam R Younis

Clinical pharmacology and therapeutics (2024)

引用0浏览0WOS引用

Supplementary Data DS1 from Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma

Xuyang Song,Robin K. Kelley,Anis A. Khan,Nathan Standifer,Diansong Zhou,KyoungSoo Lim,Rajesh Krishna,Lu Liu,Kun Wang,Patricia McCoon,Alejandra Negro,Philip He,Megan Gibbs,John F. Kurland,Ghassan K. Abou‐Alfa

openalex（2023）

引用0浏览0引用

Rare Oncology Therapeutics: Review of Clinical Pharmacology Package of Drug Approvals (2019–2023) by US FDA, Best Practices and Recommendations

Amitava Mitra,Jong Bong Lee, Douglas Steinbach,Anasuya Hazra,Rajesh Krishna

Journal of pharmacokinetics and pharmacodynamicsno. 6 (2023): 475-493

引用0浏览0引用

Model-Informed Approaches and Innovative Clinical Trial Design for Adeno-Associated Viral Vector-based Gene Therapy Product Development - A White Paper

Amitava Mitra,Mariam A Ahmed,Rajesh Krishna,Kefeng Sun,Francis D Gibbons,Olivia Campagne, Noha Rayad,Youssef M Roman,Salwa Albusaysi,Maria Burian,Islam Younis

Clinical pharmacology and therapeuticsno. 3 (2023): 515-529

引用1浏览0WOS引用

Figure S3 from Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma

Xuyang Song,Robin Kate Kelley,Anis A. Khan,Nathan Standifer,Diansong Zhou,KyoungSoo Lim,Rajesh Krishna,Lu Liu,Kun Wang,Patricia McCoon,Alejandra Negro,Philip He,Megan Gibbs,John F. Kurland,Ghassan K. Abou-Alfa

crossref（2023）

引用3浏览0引用

Use of Pharmacodynamic Modeling for Bayesian Information Borrowing in Pediatric Clinical Trials

Bernard Sebastien,S. Y. Amy Cheung,Solange Corriol-Rohou,Margaret Gamalo-Siebers,Rana Jreich,Rajesh Krishna,Jing Liu

JOURNAL OF BIOPHARMACEUTICAL STATISTICS（2023）

引用2浏览0WOS引用

Figure S1 from Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma

openalex（2023）

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn